Express News | Fuyuan Pharmaceutical: Lactofructose oral solution obtained drug registration certificate
Pacific released a research report on April 25 stating that it gave Fuyuan Pharmaceutical (601089.SH) a purchase rating. The main reasons for the rating include: 1) Q1 revenue was under pressure for a short time, and performance achieved relatively rapid
Pacific released a research report on April 25 stating that it gave Fuyuan Pharmaceutical (601089.SH) a purchase rating. The main reasons for the rating include: 1) Q1 revenue was under pressure for a short time, and performance achieved relatively rapid growth; 2) the company's net interest rate continued to improve and profitability continued to increase; 3) the reserves of ongoing research projects are abundant, which are expected to continue to contribute to incremental revenue. (Mainichi Keizai Shimbun)
Fuyuan Pharmaceutical (601089): Profitability continues to improve, and new products are expected to be released
Incident: On April 24, the company released its report for the first quarter of 2024. 2024Q1 achieved operating revenue of 803 million yuan, a year-on-year decrease of 2.01%, and net profit to mother of 133 million yuan, an increase of 16.60% year-on-year
Fuyuan Pharmaceutical (601089.SH): Net profit of 133 million yuan in the first quarter increased 16.60% year over year
On April 23, Ge Longhui Pharmaceutical (601089.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 803 million yuan, down 2.01% year on year; net profit attributable to shareholders of listed companies was 133 million yuan, up 16.60% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 124 million yuan, up 11.86% year on year; basic earnings per share were 0.28 yuan.
Fuyuan Pharmaceutical (601089.SH): The company's main products in the field of diabetes drugs are reprignide tablets, etc.
Gelonghui, April 17丨Fuyuan Pharmaceutical (601089.SH) said on the investor interactive platform that the company's main products in the field of diabetes drugs are regaglinide tablets, gliclazide sustained-release tablets, acarbose tablets, etc.
Beijing Foyou PharmaLTD's (SHSE:601089) Earnings Are Weaker Than They Seem
Beijing Foyou Pharma CO.,LTD (SHSE:601089) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders have noticed something concerning in the numbers. SHSE:6010
Pacific released a research report on April 9 stating that it gave Fuyuan Pharmaceutical (601089.SH) a purchase rating. The main reasons for the rating include: 1) the growth rate of Q4 revenue is slowing, and the impact of collection is expected to be cl
Pacific released a research report on April 9 stating that it gave Fuyuan Pharmaceutical (601089.SH) a purchase rating. The main reasons for the rating include: 1) the growth rate of Q4 revenue is slowing, and the impact of collection is expected to be cleared within 2024; 2) the growth rate of the main business is steady, and the net interest rate continues to improve; 3) the increase in R&D investment and abundant reserves of products under development; 4) the increase in the dividend ratio to continue to give back to investors. (Mainichi Keizai Shimbun)
Fuyuan Pharmaceutical (601089.SH): Has not cooperated with the Pangu Grand Model
Gelonghui, April 2 | Fuyuan Pharmaceutical (601089.SH) said on an interactive platform that the company has not cooperated with the Pangu Big Model at present.
Express News | The Social Security Fund appeared as the top ten tradable shareholders of 192 individual stocks in the fourth quarter
Fuyuan Pharmaceutical (601089): Q4 performance was slightly lower than expected, profitability continued to increase throughout the year
Incident: The company released its 2023 annual report. In 2023, the company achieved operating income of 3.340 billion yuan, an increase of 3.07% over the previous year, and net profit to mother was 489 million yuan, an increase of 11.36% over the previous year, after deducting non-return to mother
Fuyuan Pharmaceutical (601089.SH) announced 2023 annual results, net profit of 489 million yuan, an increase of 11.36% by 5 yuan per 10
Fuyuan Pharmaceutical (601089.SH) disclosed its 2023 annual report. The company achieved operating income of 33 during the reporting period...
Express News | Fuyuan Pharmaceutical: Net profit increased 11.36% year-on-year in 2023, and plans to pay 10 to 5 yuan
Express News | Fourteen companies disclosed their share repurchase plans for the first time. Qianzhao Optoelectronics plans to repurchase the highest of no more than 300 million yuan
Fuyuan Pharmaceutical (601089.SH): A total of 2.09% shares have been repurchased at a cost of 149 million yuan
Gelonghui, March 25, 丨 Fuyuan Pharmaceutical (601089.SH) announced that as of March 25, 2024, the company had repurchased a total of 1.018 million shares through centralized bidding transactions, accounting for about 2.09% of the company's total share capital, an increase of 0.70% compared with the previous disclosure. The minimum transaction price was RMB 14.37 per share, the highest transaction price was RMB 15.59 yuan/share, and the total amount of capital paid was RMB 149 million (not including transaction fees).
Express News | Fuyuan Pharmaceutical: Telmisartan hydrochlorothiazide tablets obtained a drug registration certificate
Fuyuan Pharmaceutical (601089.SH): A total cost of 98.166,600 yuan to buy back 1.39% of the shares
Gelonghui, March 7, 丨 Fuyuan Pharmaceutical (601089.SH) announced that as of March 7, 2024, the company had repurchased 6,687,200 shares through centralized bidding transactions. The repurchased shares accounted for about 1.39% of the company's total share capital, an increase of 0.84% compared with the previous disclosure. The highest transaction price was 14.91 yuan/share, the lowest price was 14.37 yuan/share, and the total amount paid was 98,166,590.92 yuan.
Foyou Pharma Gets Nod for Ezetimibe and Simvastatin Tablets
Beijing Foyou Pharmaceutical (SHA:601089) received the approval of China's National Medical Products Administration to produce and market the ezetimibe and simvastatin tablets. The drug was developed
Fuyuan Pharmaceutical (601089.SH): A total of 2,637,700 shares were purchased at a cost of 38.375 million yuan
Gelonghui, March 1, 丨 Fuyuan Pharmaceutical (601089.SH) announced that as of February 29, 2024, the company had repurchased 2,637,900 shares through centralized bidding transactions. The repurchased shares accounted for about 0.55% of the company's total share capital. The highest transaction price was 14.75 yuan/share, the lowest price was 14.37 yuan/share, and the total amount paid was 38.327,500 yuan (excluding transaction fees).
Express News | Fuyuan Pharmaceutical: Ezemeb Simvastatin Tablets Obtain Drug Registration Certificate
Fuyuan Pharmaceutical (601089.SH): Initial repurchase of 925,000 shares
Gelonghui, Feb. 28 | Fuyuan Pharmaceutical (601089.SH) announced that on February 28, 2024, the number of shares repurchased for the first time through centralized bidding transactions was 925,000 shares, accounting for about 0.19% of the company's total share capital. The minimum transaction price was RMB 14.37 per share, the highest transaction price was RMB 14.59 per share, and the total amount of capital paid was RMB 13,383,073.00 (not including transaction fees).
No Data